Tracers / [177Lu]Lu-DOTA-PEG7-tetrazine

[177Lu]Lu-DOTA-PEG7-tetrazine

Also written as [Lu-177]Lu-DOTA-PEG7-tetrazine
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
preclinical study
Syntheses indexed
1
Preclinical only, no clinical indication yetFibroblast activation / tumour stroma

What it is

Compound class
DOTA-PEG7-tetrazine, click-chemistry pretargeting effector for TRT
Target / mechanism
Click-chemistry pretargeting agent (tetrazine) reacting with TCO-modified FAP-targeted single-domain antibody PMID 39266288
Clinical application
Pancreatic ductal adenocarcinoma (PDAC), targeted radionuclide therapy via FAP-expressing tumor stroma PMID 39266288
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis————DOTA-PEG7-tetrazine39266288
2024 J Nucl Med
Information on chemical structures ... bioconjugation, radiochemistry, in vitro and in vivo assays, and dosimetry are available in the supplemental materials

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-PEG7-tetrazine, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39266288. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39266288: '[177Lu]Lu-DOTA-PEG7-tetrazine'. Stage set/updated at stage 23 from PMID 39266288: 'A TRT study in a pancreatic ductal adenocarcinoma (PDAC) patient-derived xenograft (PDX) model was performed as a pilot study for sdAb-based pretargeting applications.'.